These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

171 related items for PubMed ID: 8334029

  • 1. 24,25-dihydroxy vitamin D3 treatment inhibits parathyroid-stimulated adenylate cyclase in iliac crest biopsies from uremic patients.
    Mortensen BM, Aarseth HP, Ganss R, Haug E, Gautvik KM, Gordeladze JO.
    Bone; 1993; 14(2):125-31. PubMed ID: 8334029
    [Abstract] [Full Text] [Related]

  • 2. Alterations in serum and urine parameters reflecting bone turnover in uremic patients during treatment with 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3.
    Mortensen BM, Gordeladze JO, Lyngdal PT, Aarseth HP, Gautvik KM.
    Miner Electrolyte Metab; 1993; 19(2):78-85. PubMed ID: 8377728
    [Abstract] [Full Text] [Related]

  • 3. 1alpha(OH)D3 One-alpha-hydroxy-cholecalciferol--an active vitamin D analog. Clinical studies on prophylaxis and treatment of secondary hyperparathyroidism in uremic patients on chronic dialysis.
    Brandi L.
    Dan Med Bull; 2008 Nov; 55(4):186-210. PubMed ID: 19232159
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6. Bone turnover in rats treated with 1,25-dihydroxyvitamin D3, 25-hydroxyvitamin D3 or 24,25-dihydroxyvitamin D3.
    Mortensen BM, Gautvik KM, Gordeladze JO.
    Biosci Rep; 1993 Feb; 13(1):27-39. PubMed ID: 8392394
    [Abstract] [Full Text] [Related]

  • 7. The effect of parathyroid hormone (PTH) and 24,25-dihydroxy-vitamin D3 on adenylyl cyclase of iliac crest biopsies: diagnostic and prognostic tool for evaluation and treatment of uremic patients.
    Gordeladze JO, Mortensen B, Nordal K, Halse J, Dahl E, Aksnes L, Gautvik KM.
    Scand J Clin Lab Invest Suppl; 1987 Feb; 186():13-20. PubMed ID: 3496656
    [Abstract] [Full Text] [Related]

  • 8. PTH-stimulated adenylate cyclase activity and bone histomorphometry in iliac crest biopsies in the evaluation of uremic patients: a pilot study with the use of artificial intelligence.
    Jablonski G, Nordahl K, Halse J, Dahl E, Aksnes L, Gautvik KM, Gordeladze JO.
    Miner Electrolyte Metab; 1993 Feb; 19(6):351-61. PubMed ID: 8164616
    [Abstract] [Full Text] [Related]

  • 9. [Changes in mineral metabolism in stage 3, 4, and 5 chronic kidney disease (not on dialysis)].
    Lorenzo Sellares V, Torregrosa V.
    Nefrologia; 2008 Feb; 28 Suppl 3():67-78. PubMed ID: 19018742
    [Abstract] [Full Text] [Related]

  • 10. Marked suppression of secondary hyperparathyroidism by intravenous administration of 1,25-dihydroxy-cholecalciferol in uremic patients.
    Slatopolsky E, Weerts C, Thielan J, Horst R, Harter H, Martin KJ.
    J Clin Invest; 1984 Dec; 74(6):2136-43. PubMed ID: 6549016
    [Abstract] [Full Text] [Related]

  • 11. Comparison between 1alpha(OH)D3 and 1,25(OH)2D3 on the suppression of plasma PTH levels in uremic patients, evaluated by the 'whole' and 'intact' PTH assays.
    Brandi L, Egfjord M, Olgaard K.
    Nephron Clin Pract; 2005 Dec; 99(4):c128-37. PubMed ID: 15722644
    [Abstract] [Full Text] [Related]

  • 12. Long-term administration of vitamin D3 metabolites alters PTH-responsive osteoblastic adenylate cyclase in rats.
    Mortensen B, Gordeladze JO, Aksnes L, Gautvik KM.
    Calcif Tissue Int; 1990 May; 46(5):339-45. PubMed ID: 2159835
    [Abstract] [Full Text] [Related]

  • 13. Effect of PTH and 1,25(OH)2D3 on renal 25(OH)D3 metabolism, adenylate cyclase, and protein kinase.
    Armbrecht HJ, Wongsurawat N, Zenser TV, Davis BB.
    Am J Physiol; 1984 Jan; 246(1 Pt 1):E102-7. PubMed ID: 6320659
    [Abstract] [Full Text] [Related]

  • 14. In vivo regulation of chromogranin A messenger ribonucleic acid in the parathyroid by 1,25-dihydroxyvitamin D: studies in normal rats and in chronic renal insufficiency.
    Soliman E, Canaff L, Fox J, Hendy GN.
    Endocrinology; 1997 Jun; 138(6):2596-600. PubMed ID: 9165053
    [Abstract] [Full Text] [Related]

  • 15. Effect of 24,25(OH)2D3 on PTH levels and bone histology in dogs with chronic uremia.
    Olgaard K, Finco D, Schwartz J, Arbelaez M, Teitelbaum S, Avioli L, Klahr S, Slatopolsky E.
    Kidney Int; 1984 Dec; 26(6):791-7. PubMed ID: 6335904
    [Abstract] [Full Text] [Related]

  • 16. Oral administration of 24,25(OH)2D3 suppresses the serum parathyroid hormone levels of dialysis patients.
    Ben-Ezer D, Shany S, Conforty A, Rapoport J, Edelstein S, Bdolah-Abram T, Kafka DR, Chaimovitz C.
    Nephron; 1991 Dec; 58(3):283-7. PubMed ID: 1896092
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Modulation of parathyroid hormone-sensitive adenylate cyclase in ROS 17/2.8 cells by dexamethasone 1,25-dihydroxyvitamin D3 and protein kinase C.
    Rao LG, Wylie JN.
    Bone Miner; 1993 Oct; 23(1):35-47. PubMed ID: 8274878
    [Abstract] [Full Text] [Related]

  • 19. Differential effects of parathyroid hormone on the renal 1,25-dihydroxyvitamin D3 and 24,25-dihydroxyvitamin D3 production of young and adult rats.
    Armbrecht HJ, Wongsurawat N, Zenser TV, Davis BB.
    Endocrinology; 1982 Oct; 111(4):1339-44. PubMed ID: 6981502
    [Abstract] [Full Text] [Related]

  • 20. Effects of 1alpha,25-dihydroxy-16ene, 23yne-vitamin D3 on osteoblastic function in human osteosarcoma SaOS-2 cells: differentiation-stage dependence and modulation by 17-beta estradiol.
    Rao LG, Sutherland MK, Reddy GS, Siu-Caldera ML, Uskokovic MR, Murray TM.
    Bone; 1996 Dec; 19(6):621-7. PubMed ID: 8968029
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 9.